BioSig Strengthens Advisory Board with Addition of Edwin Wang

BioSig Technologies, Inc. (NASDAQ: BSGM) is proud to welcome Edwin Wang to its Advisory Board. The cutting-edge digital signal processing company is revolutionizing intracardiac signal visualization with its proprietary PURE EP™ System, providing unparalleled accuracy and precision. Mr. Wang’s expertise and guidance will propel the Company to its next stage of success.

Mr. Wang is a trailblazer in the private equity, venture capital, merchant banking, and family office investing fields, with over 20 years of successful experience in these areas.

He is the founder of Accretive Capital Partners LLC, a pioneering direct investment sponsor that has raised and invested in a top quartile secondary direct investment fund, Accretive Exit Capital Partners LP, with key investors such as HarbourVest Partners, Goldman Sachs Vintage Funds, and Paul Capital Partners. In his advisory role, Mr. Wang has been responsible for more than $2 billion in portfolio and fund restructurings.

Mr. Wang achieved remarkable success in the financial sector. At Asymmetry Capital LLC, he successfully restructured and liquidated a $1 billion venture capital portfolio from Zero Stage Capital—the predecessor of Moderna. His accomplishments have been documented in multiple Harvard Business School case studies and The Deal Magazine.

Moreover, after an 8-year investment banking career at Credit Suisse and Lehman Brothers, Mr. Wang spearheaded the formation of Asia Corporate Partners Fund—one of the earliest institutional direct investment funds for China.

The fund was backed by leading global asset managers, including CalPERS, CalSTRS, Capital Group, and China Development Bank (Taiwan). Some of its core holdings were Hon Hai Precision (Foxconn), Taiwan Semiconductor Manufacturing, and Texas Instruments/Acer.

Mr. Wang achieved great academic success, earning his B.A. in Economics from Columbia University and later being invited as a Visiting Fellow in Finance to the MIT Sloan School of Management by the late Nobel laureate in Economics, Dr. Franco Modigliani. His opportunity to study under such an esteemed figure was a testament to his dedication to learning and the high regard in which his peers held him.

BioSig Technologies is delighted to welcome Edwin Wang to its advisory team as a highly esteemed investment strategist. With a wealth of experience in global capital markets and an impressive history of success in private equity growth capital and technology investing, Ed is sure to be an invaluable asset to the company’s capital markets strategy and its goal of growing its shareholder base.

Ken Londoner, Chairman, CEO and Founder of BioSig, expressed his enthusiasm for Ed’s appointment, stating, “We warmly welcome Ed to our advisory team.”

Edwin Wang is thrilled to join forces with Ken Londoner and the BioSig team in their groundbreaking mission to improve patient outcomes and save lives. With a unique blend of strategic vision, technical prowess and sound execution, Londoner has been a valued leader in the intersection of finance and industry for the past quarter century.

Wang has made numerous investments in technology-enabled healthcare companies, several of which have had a profound impact on medicine and public health, particularly in the fight against cardiovascular disease, which costs the U.S. alone an estimated $109B annually in direct expenses. BioSig Technologies is leading the way in digital signal processing and AI to combat cardiac arrhythmias, and Wang is honored to be a part of this vital mission.

About BioSig Technologies

BioSig Technologies is revolutionizing the treatment of cardiovascular arrhythmias with cutting-edge digital signal processing technology. By partnering with leading physicians, experts and healthcare professionals in electrophysiology, we are dedicated to improving healthcare outcomes, reducing costs and saving lives. Our innovative solutions are helping to shape the future of EP and transforming the way arrhythmias are treated.

The PURE EP™ System, a revolutionary FDA 510(k) cleared non-invasive device, is paving the way for superior cardiac ablation procedures. This pioneering technology allows physicians to access real-time signal visualization, enabling targeted and efficient procedures with increased efficacy. It’s no surprise that this groundbreaking product is the first of its kind from our company!

The PURE EP™ System is revolutionizing healthcare, as it is now an essential part of well-respected healthcare systems, such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.

A recent study published in the Journal of Cardiovascular Electrophysiology highlighted the system’s efficacy, as it found that electrophysiologists rated PURE EP™ as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating. This system is now in a national commercial launch and is changing the way we think about healthcare.

The EP market is expected to skyrocket to a staggering $16 billion by 2028, promising an impressive 11.2% growth rate. This presents an exciting opportunity for investors and industry players looking to capitalize on this expanding market.

Leave a Comment